A second peer-review paper has endorsed the performance of ePat Technologies’ (ASX: EPT) PainChek app, confirming previous clinical findings published in the Journal of Alzheimer’s Disease.
To be published in the Dementia and Geriatric Cognitive Disorders journal, the second study assessed 34 people with moderate to severe dementia aged between 68 and 93 years across two Western Australia-based aged care facilities.
Patients were assessed with PainChek and the current Abbey Pain Scale, with results compared. The study revealed PainChek distinguished pain under different conditions including rest and movement.
“This study confirms the PainChek app as a reliable and accurate pain assessment tool for people who are unable to verbalise their pain effectively,” ePat chief executive officer and managing director Philip Daffas said.
“We are already receiving an overwhelming positive feedback on the clinical utility of PainChek and its impact on residents on a daily basis from our clients in Australia,” he said.
He added the study which will be published next quarter will provide more evidence to health care professionals of the app’s effectiveness, which will facilitate ePat’s ongoing expansion.
The app was launched in October and less than a month later, a South Australian operator purchased the software for use on its residents – making it the company’s first residential aged care sale.
PainChek works by capturing a brief video of an individual on a smartphone or tablet.
Facial recognition software analyses the video in real-time to pick up on facial and micro-expressions that indicate pain. The data is combined with other pain indicators such as behaviour, vocalisation and movement to calculate a severity score.
Appropriate pain relief can then be administered and monitored for effectiveness.
According to the ePat, PainChek is efficient and easy to use and once it has cornered the global aged care market, it plans to target the technology at infants and children who haven’t learned to speak.